Skip to main content

Table 2 Risk analysis results of DMRs methylation levels of imprinted genes and CHD occurrence

From: DNA methylation abnormalities of imprinted genes in congenital heart disease: a pilot study

Imprinted genes Quantile percentages Controls
n (%)
CHD
n (%)
Adjusted ORa
(95% CIb)
Adjusted P value
GRB10 Q1c (< 39.67%) 6(26.1%) 1(4%) 1(reference)  
  Q2–Q3 d (39.67%–44%) 11(47.8%) 3(12%) 1.64(0.14–19.39) 0.696
  Q4e (> 44%) 6(26.1%) 21(84%) 21.00(2.10–210.14) 0.01
MEST Q1 (< 49.36%) 5(22.7%) 1(5%) 1(reference)  
  Q2–Q3 (49.36%–56.07%) 12(54.5%) 9(45%) 3.75(0.371–37.95) 0.263
  Q4 (> 56.07%) 5(22.7%) 10(50%) 10.00(0.907–110.28) 0.06
PEG10 Q1 (< 45.2%) 5(22.7%) 14(56%) 16.80(1.60–176.23) 0.019
  Q2–Q3 (45.2%–55.7%) 11(50%) 10(40%) 5.46(0.56–53.52) 0.145
  Q4 (> 55.7%) 6(27.3%) 1(4%) 1(reference)  
NAP1L5 Q1 (< 67.14%) 6(26.1%) 9(45%) 3.50(0.64–19.20) 0.149
  Q2–Q3 (67.14%–71.29%) 10(43.5%) 8(40%) 1.87(0.36–9.64) 0.456
  Q4 (> 71.29%) 7(30.4%) 3(15%) 1(reference)  
INPP5Ff Q1 (< 70.39%) 4(23.5%) 17(77.3%) 11.06(2.47–49.53) 0.002
  Q2–Q4 (≥ 70.39%) 13(76.5%) 5(22.7%) 1(reference)  
PLAGL1 Q1 (< 40.76%) 6(24%) 11(42.3%) 11.00(1.06–114.09) 0.045
  Q2–Q3 (40.76%–45.82%) 13(52%) 14(53.8%) 6.46(0.68–61.16) 0.104
  Q4 (> 45.82%) 6(24%) 1(3.8%) 1(reference)  
MEG3f Q1 (< 41.83%) 6(25%) 16(80%) 12.00(2.86–50.31) 0.001
  Q2–Q4 (≥ 41.83%) 18(75%) 4(20%) 1(reference)  
  1. aOdds ratio
  2. bConfidence interval
  3. c25th percentile
  4. d25th percentile to 75th percentile
  5. e75th percentile. Cut-off value was defined as 25th and 75th percentiles of the control group methylation level. Adjusted for sex by logistic regression
  6. fIndicates that the maximum value of the imprinting gene cases was less than 75% of control group and could not be calculated, so there were divided into two groups